Brachytherapy Boost Ups Survival in Locally Advanced Cervical Cancer

MONDAY, March 25, 2019 -- The current standard of care (SOC) for advanced cervical cancer -- external beam radiation therapy (EBRT) and chemotherapy in combination with brachytherapy -- provides significantly higher overall survival over...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions: 3D-HDR-BT achieves favorable clinical outcomes with mild late toxicity in patients with locally rNPC. Introduction Nasopharyngeal carcinoma (NPC), a tumor of epithelial origin, is a malignant disease of the head and neck common in southern China, especially in Guangdong province (1). As a result of advances in modern imaging and irradiation techniques, the 5-year overall survival (OS) of patients with newly diagnosed NPC without metastasis has reached 75% after external beam radiotherapy (EBRT) in Asia (2, 3). However, local recurrence, which occurs in 18–40% of patients, remains a major reason for...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Current recommendation for locally advanced cervical cancer includes pelvic external beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy. Involvement of pelvic lymph nodes is a...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Publication date: Available online 27 March 2019Source: Gynecologic Oncology ReportsAuthor(s): Lisa A. Rubinsak, Mishka Terplan, Caitlin E. Martin, Emma C. Fields, William P. McGuire, Sarah M. TemkinAbstractThe purpose of this study was to identify the prevalence of substance use disorder and its association with adherence to treatment and survival in locally advanced cervical cancer patients treated with primary radiation therapy. This is a retrospective case series of locally advanced cervical cancer patients with substance use disorder in a single academic institution treated with radiation therapy between 2005 and 2016...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
ConclusionsNeoadjuvant chemoradiation therapy effectively downstages the majority of locally advanced type II endometrial cancers, thereby increasing the likelihood of achieving complete resection with negative margins.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
We examined whether this urban-rural paradox exists among patients with cervical cancer. METHODS: We identified individuals diagnosed with cervical cancer from 2004 to 2013 using a statewide cancer registry linked to multi-payer, insurance claims. Our primary outcome was receipt of guideline-concordant care: surgery for stages IA1-IB1; external beam radiation therapy (EBRT), concomitant chemotherapy, and brachytherapy for stages IB2-IVA. We estimated risk ratios (RR) using modified Poisson regressions, stratified by urban/rural location, to examine the association between distance to nearest facility and receipt of tr...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Conclusion: Concomitant brachytherapy and chemotherapy with platinum compounds can be well tolerated and is effective in the treatment of locally advanced cervical cancer. PMID: 30360600 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Publication date: Available online 16 August 2018Source: Gynecologic Oncology ReportsAuthor(s): Josette C. Dawkins, Gregory K. Lewis, Eugene P. ToyAbstractCervical cancer is the most common gynecologic malignancy worldwide and the third most common gynecologic cancer in the USA. Improved screening methods such as liquid-based cytology accompanied by Human Papilloma Virus (HPV) co-testing have contributed to a declining incidence of cervical cancer. There are approximately 13,000 new cases per year in the United States, accounting for 4200 deaths (Siegel et al., 2011). Pelvic organ prolapse increases with age, obesity and p...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
ConclusionsTreatment with EBRT or IB does not appear to impair sexual function in women with gynecologic cancer. Age less than 50, concurrent chemotherapy, and cervical cancer may place women with gynecologic cancer at higher risk for decreased sexual function following radiation.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
DiscussionRapidArc has an obvious advantage in improving the degree of target coverage, improving organs at risk, sparing healthy tissue, and significantly reducing the treatment time. FDG-PET/CT can increase the agreement between biopsies and delineated tumor volume and has the potential to positively impact the course of treatment. The Comet assay is attractive as a potential clinical test of tumor radiosensitivity. During radiotherapy, accurately defining disease areas is critical to avoid the unnecessary irradiation of normal tissue. Based on FDG-PET/CT and Comet assay, higher doses can be safely delivered to accurate ...
Source: Trials - Category: Research Source Type: clinical trials
This report is based on site visits to NCI Paraguay by HVO volunteers in 2012, 2013, and 2016, with a follow-up report from the site in 2017. During the study period, increased access to external beam radiation and brachytherapy led to a decrease in wait time to start radiation from 2 to 3 months to 4–6 weeks. The center transitioned from 2-dimensional (2D) to 3-D planning and was able to offer concurrent chemotherapy and radiation, including brachytherapy, to patients with locally advanced cervical cancer. Based on the American Society of Clinical Oncology's resource-stratified clinical guidelines, from 2012 to ...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | External Beam Therapy | Pharmaceuticals | Radiation Therapy